Future work will be needed to more precisely identify the genes controlled by ESRP1 and ESRP2 that are important in aggressive prostate cancer, how they result in tumour growth, and how expression of these genes are modulated in response to ADT and during tumour metastasis. Here, ESRP2 is linked to prostate carcinoma.